Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 828

Showing 51-75 of 828 citing articles:

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
Stem cell membrane-camouflaged targeted delivery system in tumor
Weiyue Zhang, Xin Huang
Materials Today Bio (2022) Vol. 16, pp. 100377-100377
Open Access | Times Cited: 45
Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Yinan Ding, Luhong Wang, Han Li, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 43
Dostarlimab: A Review
Bárbara Costa, Nuno Vale
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1031-1031
Open Access | Times Cited: 41
Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
Ke-Wang Luo, Ning Li, Wei Ye, et al.
Molecules (2022) Vol. 27, Iss. 14, pp. 4638-4638
Open Access | Times Cited: 40
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma
Zhiqiang Chen, Xueliang Zuo, Juan Cai, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 38
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
Kezhen Li, Jing Chen, Yingjie Hu, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 76-85
Closed Access | Times Cited: 36
Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
Abdelrahman Abaza, Faten Sid Idris, Humna Anis Shaikh, et al.
Cureus (2023)
Open Access | Times Cited: 34
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 33
The CD47-SIRPα axis is a promising target for cancer immunotherapies
Hao Yu, Xinxuan Zhou, Yiling Li, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110255-110255
Closed Access | Times Cited: 32
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Bin Wang, Han Yin, Yuyu Zhang, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy
Ziyin Chen, Ziqi Yue, Kaiqi Yang, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 26
Open Access | Times Cited: 29
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
Yuxiang Ma, Jinhui Xue, Yuanyuan Zhao, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006654-e006654
Open Access | Times Cited: 27
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Bo Hou, Ting Chen, He Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Jinxin Li, Qiwei Wang, Yingli Han, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 26
Recent advances and future perspectives in the therapeutics of prostate cancer
Ganji Lakshmi Varaprasad, Vivek Gupta, K. Satya Prasad, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 26
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 25
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Kohei Okuyama, Tomofumi Naruse, Souichi Yanamoto
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 24
Cancer Cell Membrane-Coated Gambogic Acid Nanoparticles for Effective Anticancer Vaccination by Activating Dendritic Cells
Fengli Huang, Qun Zhang, Jie Xiao, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 2261-2273
Open Access | Times Cited: 23
Current Status in Rechallenge of Immunotherapy
Han Hu, Ke Wang, Rong Jia, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2428-2442
Open Access | Times Cited: 23
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 23
Role of regulation of PD-1 and PD-L1 expression in sepsis
Teng Zhang, Yujing Li, Tao Ma
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 22
Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
Xiaowei Liang, Hongwei Gao, Jian Xiao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 22
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 22
Small-molecule agents for cancer immunotherapy
Fang Wang, Kai Fu, Yujue Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 905-952
Open Access | Times Cited: 22

Scroll to top